-The Times of India A once-a-week medicine for diabetics — a disease that affects nearly 63 million Indians — could soon become a reality. Studies on diabetes have seen a global upsurge, with the latest data showing that bio-pharmaceutical research companies across the globe are busy developing 221 innovative new medicines. The drugs, which will help around 347 million patients include new therapies that target key abnormalities of pancreatic cells, increase insulin secretion...

-The Indian Express The government’s proposal to price-control certain drugs will create more problems than it will solve From clothes to cars, prices of consumer products the world over are determined taking into account input costs, margins and competition, popularly called the cost-based pricing system. Departing from this sound, fair, tried and tested principle of commerce, the government’s new drug pricing policy, approved by the Group of Ministers headed by Sharad Pawar,...

-Live Mint NAC wants Rashtriya Swasthya Bima Yojna to be absorbed into new policy for universal health coverage  The National Advisory Council (NAC), which sets the policy agenda for the Congress party led United Progressive Alliance (UPA) government, wants the Rashtriya Swasthya Bima Yojna (RSBY) insurance scheme to be absorbed into the new policy for universal health coverage (UHC), taking the latter closer to realization.   This is part of the government’s bid to move...

-The Hindu A 2012 WHO study ranks India third — behind Myanmar and Bangladesh — among countries that fail to provide health cover to people. A 2011 study reported in The Lancet on ‘Healthcare and equity’ confirms this: every year, at least 39 million people here fall into poverty due to private out-of-pocket health expenditure. A vast majority of Indians do not have access to healthcare or essential drugs. By the...

-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...